ESTIMATED NET COST IMPACTS ASSOCIATED WITH IMPROVED DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION

Author(s)

Orlowski A1, Smith W1, Ashton R1, Belsey J2
1Imperial College Health Partners, London, UK, 2JB Medical Ltd, Sudbury, UK

OBJECTIVES: Estimate net cost impacts of interventions to close diagnosis and treatment gaps in management of atrial fibrillation (AF) and stroke risk. METHODS: Currently, 78% of patients with known AF are offered, started, and maintained on appropriate treatment. The Academic Health Science Network’s AF Business Case Model, launched in 2017, uses publicly reported national and local data on projected prevalence, AF management in primary and secondary care, and anticoagulant treatment to identify specific gaps. The model assumes that interventions will be implemented over 12 months and calculates net cost impacts over the following 3 years in four areas: detection (including potential screening of people >65 years), risk assessment (based on CHADS-VASc score of AF stroke risk), treatment initiation, and treatment adequacy. We applied 2016/17 data to identify gaps at the national level in England and assumed that the interventions would be achieved in 100% of patients. RESULTS: The AF register included 1,065,569 patients (prevalence 1.85%). The model estimated, however, that prevalence should be 2.50% (1.4 million patients), giving a detection gap of 25.9%. Screening of all undetected patients and improved diagnostic interventions coupled with adequate anticoagulation would cost £47.1 million. Risk assessments had not been performed in 13,592 (3.1%) patients. With 100% assessment, the reduced stroke risk would be associated with a saving of £4.4 million. Among 877 964 patients eligible for anticoagulation, 165,355 (19%) were not receiving treatment, and among the 712,609 being treated, anticoagulation was inadequate in 191,289 (30%). Starting treatment in all untreated patients would save £53.7 million and achieving adequate anticoagulation in all would save a further £136.6 million. The total achievable saving over 3 years, therefore, would be £147.7 million. CONCLUSIONS: Addressing AF diagnosis and management gaps, especially adequacy of anticoagulation, would lead to significant savings across England, even with the cost of introducing screening.

Conference/Value in Health Info

2018-09, ISPOR Asia Pacific 2018, Tokyo, Japan

Value in Health, Vol. 21, S2 (September 2018)

Code

PCV57

Topic

Economic Evaluation, Health Service Delivery & Process of Care

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies, Prescribing Behavior, Treatment Patterns and Guidelines

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×